To investigate the role of p53–FDXR signaling in MASLD, we assessed the expression of FDXR, p53, and p21 (a canonical p53 target gene) in liver samples from patients with nonalcoholic fatty liver or nonalcoholic steatohepatitis (NAFL/NASH; recently redefined as MASLD/MASH22), as well as from mice fed a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD), a widely used MASH mice model23. This evidence concerns the gene TP53 and metabolic dysfunction-associated steatohepatitis.